PCSA (Processa Pharmaceuticals) Cash per Share: $0.63 (As of Mar. 2026)


PCSA Processa Pharmaceuticals Inc PCSA
28 GF Score
Price $2.16
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Cash per Share?

Processa Pharmaceuticals PCSA +9.64% 28 Cash per Share is $0.63 as of Mar. 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Processa Pharmaceuticals's Cash per Share for the quarter that ended in Mar. 2026 was $0.63.

Processa Pharmaceuticals  (NAS:PCSA) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Processa Pharmaceuticals Cash per Share Related Terms

Processa Pharmaceuticals Cash per Share Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Cash per Share Chart

Processa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 532.19 203.25 92.28 8.05 2.15

Processa Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.73 4.31 2.98 2.15 0.63
PCSA
28GF Score
Processa Pharmaceuticals Inc PCSA
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Processa Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=5.537/2.57
=2.15

Processa Pharmaceuticals's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=1.691/2.68
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.63 mean?
Processa Pharmaceuticals (PCSA) has a Cash per Share of $0.63 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Processa Pharmaceuticals and its competitors.
Is Processa Pharmaceuticals' Cash per Share too high?
Processa Pharmaceuticals' current Cash per Share is $0.63. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' Cash per Share compare to ELAB and MBIO?
Processa Pharmaceuticals' Cash per Share of $0.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current Cash per Share is $0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current Cash per Share of $0.63. The current Cash per Share is $0.63. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Cash per Share is $0.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score

Get the complete analysis for PCSA

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price